Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2017 ASCO Annual Meeting /
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy

2nd - 6th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.17
Views: 2316

Prof Valentina Guarneri - Università degli Studi di Padova, Padua, Italy

Prof Guarneri speaks with ecancer at ASCO 2017 about results from a phase III multicentre trial of  trastuzumab in adjuvant setting with chemotherapy for 9 weeks vs 1 year for patients with HER2 breast cancer.

The 5-year disease free survival rate was 87.5% for the long arm compared to 85.4% for the shorter arm.

She notes that the shorter length of treatment with adjuvant trastuzumab significantly lowers risk of cardiac events.

The reduced overall cost of shorter treatment may also lower barriers to treatment access.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation